Information détaillée concernant le cours
Titre | Drug development: regulatory aspects and clinical trials (+CILS) |
Dates | 22.02.2018 (13 :30-17 :30 ); 05.03.2018 (13 :30-17 :00); 19.03.2018 (13 :30-17 :30 ) 22.03.2018 (13 :30-17 :00) ; 26.03.2018 (13 :30-17 :00); 16.05.2018 (13 :30-17 :30 ) |
Organisateur(s)/trice(s) | |
Intervenant-e-s | Dr Andrés Mc Allister, AMConsulting Dr Aarti Naik, Triskel Intergrated Services, Dre Sabine Latour, Debiopharm |
Description |
Objectives:
To give the students an introduction to drug development from drug discovery through to marketing, focusing on steps involved in the clinical evaluation of safety and efficacy of drug candidates, the approval and marketing of medicines, and post-marketing commitments of pharmaceutical companies.
Course Outline:
· lesson 1 Introduction (Andrés Mc Allister)
· lesson 2 Pharmacovigilance/safety (Andrés Mc Allister)
· lesson 3 Clinical protocols 1 (Andrés Mc Allister)
· lesson 4 Clinical protocols 2 (Andrés Mc Allister) lesson 5 Clinical study/organization 1 (Sabine Latour)
· lesson 6 Clinical study/organization 2 (Sabine Latour)
· lesson 7 Regulatory aspects of drug development and approval (Aarti Naik)
· lesson 8 Regulatory aspects of drug development and approval(Aarti Naik)
· lesson 9 Clinical study/organization 3 (Sabine Latour)
· lesson 10 Clinical study/organization 4 (Sabine Latour)
Endpoints for single modules:
Pharmacovigilance /safety:
The students understand how the clinical safety profile of a drug is defined during premarketing and postmarketing periods
The students understand the aims and the methods of passive pharmacovigilance vs. proactive pharmacovigilance (pharmacoepidemiology).
Clinical study/organization:
The students know how a controlled clinical study is planned, performed and monitored
The roles of the different actors, including the hospital pharmacist, are discussed
The students know what is meant by Good Clinical Practice (GCP)
The students know what a patient consent form is (informed-consent documents)
Regulatory aspects of drug development and approval:
Students will:
- understand the role of regulatory agencies in the development, approval and post-marketing lifecycle of medicines
- learn about fundamental European legislation governing the use of medicinal products in humans
- understand how medicines are approved in Europe and about different licensing procedures available in Europe
- learn about the content and format of a dossier ("marketing authorisation application") necessary for obtaining approval for medicines from regulatory agencies
|
Lieu |
22.02.2018: B02.2526; 05.03.2018: A04.2713; 19.03.2018: S4-S5; 22.03.2018: A04.2713 ; 26.03.2018: A04.2713; 16.05.2018: A04.3018 |
Information | |
Places | 10 |
Délai d'inscription | 15.02.2018 |